$45.00
Frag 17-23 is a synthetic peptide fragment derived from the amino acid sequence of human growth hormone (HGH). It is commonly studied in biochemical and laboratory research focused on understanding lipid metabolism and cellular signaling pathways associated with fat breakdown processes.
In scientific literature, Frag 17-23 is recognized as a modified segment of the HGH molecule, engineered to isolate specific metabolic activity without replicating the full hormonal structure. Researchers investigate this peptide to better understand how growth hormone fragments may influence lipolytic activity at a cellular level and how these mechanisms interact within controlled experimental environments.
Due to its specialized structure, Frag 17-23 is primarily utilized in laboratory-based studies rather than clinical or consumer applications. It is important to note that this compound is not approved for human therapeutic use, medical treatment, or dietary supplementation.
Scientific interest in HGH fragments such as Frag 17-23 continues to grow, particularly in the fields of endocrinology, metabolism research, and molecular biology. Studies aim to explore how targeted peptide sequences may contribute to broader understanding of energy regulation and fat metabolism pathways.
For researchers, Frag 17-23 represents a focused area of study within peptide science, offering insights into how small modifications in protein structure can influence biological activity in experimental models.
Ketacyn Pharmaceuticals is a specialized pharmaceutical company dedicated to providing high-quality ketamine-based products for medical use in anesthesia, pain management, and emerging therapeutic applications. Our focus is on ensuring safe, reliable, and compliant delivery of these controlled substances to healthcare professionals and institutions worldwide.
